Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenfluramine (ZX008) Phase 3 trial in CDKL5 deficiency disorder
NL-OMON56446Phase 3Recruiting
- Sponsor
- Zogenix, Inc.
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fenfluramine in CDKL5 deficiency disorder (CDD) (3 arms), sponsored by Zogenix, Inc. Primary endpoints: Percentage change from baseline in countable motor seizure frequency during titration plus maintenance and Long-term safety and tolerability in the open-label extension. Started Dec 2023; status: recruiting.
02
Drugs
fenfluramine
03
Conditions
CDKL5 deficiency disorder (CDD)
Beyond the preview
Go deeper on NL-OMON56446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56446.